FDA SEEKING PUBLIC PARTICIPATION IN ACYCLOVIR Rx-TO-OTC SWITCH REVIEW
This article was originally published in The Tan Sheet
Executive Summary
FDA SEEKING PUBLIC PARTICIPATION IN ACYCLOVIR Rx-TO-OTC SWITCH REVIEW in a May 19 public hearing scheduled by the commissioner's office that will immediately precede a review of Burroughs- Wellcome's Zovirax switch application by a joint meeting of FDA's Nonprescription Drugs Advisory Committee and Antiviral Drugs Advisory Committee.